Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
Pacific Biosciences of California, Inc. PACB incurred third-quarter 2019 adjusted loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 19 cents a year ago.
Revenues totaled $21.9 million, which missed the Zacks Consensus Estimate by 21.8%. Revenues improved 20.7% from the year-ago quarter’s tally.
Product Revenue: At this segment, revenues amounted to $18.5 million, up 22% from the prior-year quarter’s tally.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Service and Other Revenue: At this segment, revenues came in at $3.4 million, up 14% year over year.
Gross profit in the third quarter of 2019 was $6.9 million, up a significant 116.6% on a year-over-year basis. Gross margin was 31.5% of total revenues, improving significantly from the year-ago quarter’s 17.6%.
Research and Development expenses increased 4.2% to $15 million in the quarter. Further, sales, general and administrative expenses rose 48.6% to $20.1 million.
Operating expenses totaled $35 million, up 25.7% year over year.
About the Illumina & Pacific Biosciences Merger
Illumina ILMN has confirmed its merger with Pacific Biosciences. Per management, the total value of the deal is approximately $1.2 billion.
For the three months ended Sep 30, 2019, Pacific Biosciences recognized approximately $3.6 million in operating expenses pertaining to the merger.
Pacific Biosciences carries a Zacks Rank #3 (Hold).
Earnings of MedTech Majors at a Glance
Some better-ranked companies which posted solid results this earning season are NuVasive, Inc NUVA and Thermo Fisher Scientific Inc TMO, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NuVasive’s third-quarter 2019 adjusted EPS of 59 cents beat the consensus estimate by 9.3%. Its revenues of $290.8 million outpaced the consensus mark by 2.4%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Its revenues of $6.27 billion exceeded the Zacks Consensus Estimate by 1.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report
NuVasive, Inc. (NUVA): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.